Dragonfly Signs Digital Therapeutic Device Platform Development Contract with Selvas AI

Dragonfly announced on the 23rd that it has signed a contract with Selvas AI to develop an integrated operation platform for digital therapeutics devices.

This contract was signed to enhance the product competitiveness of the game-based ADHD (Attention Deficit Hyperactivity Disorder) digital therapeutics device "Guardians DTx" (working title), which Dragonfly is currently conducting exploratory clinical trials on. Both companies will develop an integrated operation platform for doctors and patients for Guardians DTx.

Digital therapeutics devices are software designed to prevent, manage, and treat diseases. To use them, a platform that connects doctors and patients and provides customized treatment services based on data is necessary. Accordingly, both companies plan to develop a platform that improves usability for both doctors and patients. In particular, Selvas AI is expected to contribute to the development of customized services due to its extensive experience in supplying platforms to numerous hospitals, institutions, and insurance companies.

Dragonfly started its digital therapeutics business in 2020. Currently, it is conducting exploratory clinical trials of Guardians DTx with Pusan National University Hospital and Pusan National University Industry-Academic Cooperation Foundation. Guardians DTx is designed for ADHD patients aged 7 to under 13 years old.

In March, Dragonfly attracted attention by being the first domestic game company to participate in the international medical device and hospital equipment exhibition KIMES 2023, where it unveiled Guardians DTx. This led to signing an MOU with Selvas AI to begin cooperation for platform development.

Dragonfly was selected for the Ministry of Health and Welfare’s health and medical technology research and development project and will receive approximately 1.7 billion KRW in funding over three years starting this year to conduct research and development in collaboration with Seoul National University Hospital, Daegu Catholic University Hospital, and Wonkwang University Hospital as partner institutions.

A Dragonfly representative stated, “Through this contract with Selvas AI, we have gained the driving force to lead the digital therapeutics market. We will proceed smoothly with the ongoing exploratory clinical trials targeting pediatric patients to advance the digital therapeutics product and, through future commercialization, provide support to ADHD patients and their caregivers.”

This content was produced with the assistance of AI translation services.